FDA Approves New HIV Treatment
The agency has approved a new HIV treatment for patients with "limited treatment options".
On March 6, 2018, FDA approved Trogarzo (ibalizumab-uiyk), a new antiretroviral medication for adult patients living with multidrug-resistant (MDR) HIV who have tried multiple HIV medications in the past and whose HIV infections cannot be successfully treated with other available therapies.
Ibalizumab-uiyk, a humanized monoclonal antibody, is the result of a partnership between Theratechnologies, a Canadian pharmaceutical company focused on developing HIV treatments, and biotechnology company TaiMed Biologics. The drug is a CD4-directed, post-attachment HIV-1 inhibitor that binds to CD4+ receptors on host cells and blocks the HIV virus from infecting the cells while preserving normal immunological function, as stated by Theratechnologies.
“[The] approval of Trogarzo by [FDA] is great news for people infected with difficult-to-treat [MDR] HIV. We look forward to bringing this much-needed therapy to
patients in the [United States] within six weeks,” said Luc Tanguay, president and CEO at Theratechnologies, in a company press release.
The drug is intended to be used in combination with other antiretroviral medications and is administered intravenously once every 14 days by a trained medical professional. FDA granted this application fast track, priority review, and breakthrough therapy designations, in addition to orphan drug designation.
“While most patients living with HIV can be successfully treated using a combination of two or more antiretroviral drugs, a small percentage of patients who have taken many HIV drugs in the past have [MDR] HIV, limiting their treatment options and putting them at a high risk of HIV-related complications and progression to death,” said Jeff Murray, MD, deputy director of the Division of Antiviral Products, FDA’s Center for Drug Evaluation and Research, in an agency press release. “Trogarzo is the first drug in a new class of antiretroviral medications that can provide significant benefit to patients who have run out of HIV treatment options. New treatment options may be able to improve their outcomes.”
Source: FDA, Theratechnologies
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
